Primavera SIGNED
Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Primavera project word cloud
Explore the words cloud of the Primavera project. It provides you a very rough idea of what is the project "Primavera" about.
Project "Primavera" data sheet
The following table provides information about the project.
| Coordinator |
NUTRIPHARMA HUNGARIA TAP ES GYOGYSZER ELOALLITO KFT
Organization address contact info |
| Coordinator Country | Hungary [HU] |
| Project website | http://www.nutripharma.hu/nutripharma/primavera-project/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2019-01-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | NUTRIPHARMA HUNGARIA TAP ES GYOGYSZER ELOALLITO KFT | HU (BUDAPEST) | coordinator | 50˙000.00 |
Map
Project objective
Age-related Macular Degeneration (AMD) is a chronic, progressive, sight-threatening disease, caused by the damage of the macula, the small, central area of the retina. People with AMD have difficulty seeing colours, details and later, to read, to drive and to work. The disease causes significant social, medical, and economic burden. Its prevalence (hidden in early stage) is estimated more 8-10% in industrialized countries (EU, USA) for people over 40 years. However, neither screening method is proposed for the early detection of AMD nor its effective treatment has been approved yet. The multivitamin products, found on the market today, have provenly low efficiency to supress early stage AMD, and rather expensive compared to their low-effectiveness. The objective of primavera project is the commercialisation of a new medical food for treatment of AMD. Our new and unique formula, Primavera, is based on immunobiotic compounds, prepared by our innovative technology, and metabolic booster compounds. The new and unique formula will expectedly have benefits on both visual functions and retinal alterations in early AMD. The success of the project will promote the growth of our company.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRIMAVERA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PRIMAVERA" are provided by the European Opendata Portal: CORDIS opendata.